Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Initial combination therapy with ambrisentan + tadalafil on pulmonary arterial hypertension‒related hospitalization in the AMBITION trial.
Vachiéry JL, Galiè N, Barberá JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Blair C, Miller KL, Langley J, Rubin LJ; AMBITION Study Group. Vachiéry JL, et al. Among authors: miller kl. J Heart Lung Transplant. 2019 Feb;38(2):194-202. doi: 10.1016/j.healun.2018.11.006. Epub 2018 Nov 22. J Heart Lung Transplant. 2019. PMID: 30522722 Free article. Clinical Trial.
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. Among authors: miller kl. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
Hoeper MM, McLaughlin VV, Barberá JA, Frost AE, Ghofrani HA, Peacock AJ, Simonneau G, Rosenkranz S, Oudiz RJ, White RJ, Miller KL, Langley J, Harris JHN, Blair C, Rubin LJ, Vachiery JL. Hoeper MM, et al. Among authors: miller kl. Lancet Respir Med. 2016 Nov;4(11):894-901. doi: 10.1016/S2213-2600(16)30307-1. Epub 2016 Oct 11. Lancet Respir Med. 2016. PMID: 27745818 Clinical Trial.
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
Coghlan JG, Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, Kuwana M, McLaughlin VV, Peacock AJ, Simonneau G, Vachiéry JL, Blair C, Gillies H, Miller KL, Harris JHN, Langley J, Rubin LJ; AMBITION investigators. Coghlan JG, et al. Among authors: miller kl. Ann Rheum Dis. 2017 Jul;76(7):1219-1227. doi: 10.1136/annrheumdis-2016-210236. Epub 2016 Dec 30. Ann Rheum Dis. 2017. PMID: 28039187 Free PMC article. Clinical Trial.
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator's Consortium Registry Analysis.
Stalker M, Grady CB, Watts A, Hwang WT, Chandrasekhara K, Sun F, Liu G, Patel D, Nieva J, Herrmann A, Marrone K, Lam VK, Velcheti V, Liu SV, Bravo Montenegro GL, Tompkins W, Patil T, Weiss J, Miller KL, Schwartzman W, Dowell JE, Shaverdashvili K, Villaruz L, Cass A, Iams W, Aisner D, Aggarwal C, Camidge DR, Sun L, Marmarelis ME. Stalker M, et al. Among authors: miller kl. JTO Clin Res Rep. 2024 Nov 12;6(1):100765. doi: 10.1016/j.jtocrr.2024.100765. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39758601 Free PMC article.
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer.
Grady CB, Hwang WT, Reuss JE, Iams W, Cass A, Liu G, Patel D, Liu SV, Montenegro GLB, Patil T, Nieva JJ, Herrmann A, Marrone KA, Lam VK, Schwartzman W, Dowell J, Villaruz LC, Miller KL, Weiss J, Sun F, Velcheti V, Camidge DR, Aggarwal C, Sun L, Marmarelis ME. Grady CB, et al. Among authors: miller kl. Pharmacoepidemiol Drug Saf. 2024 Dec;33(12):e70049. doi: 10.1002/pds.70049. Pharmacoepidemiol Drug Saf. 2024. PMID: 39586662 Free PMC article.
Corrigendum to "TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43" [Neurobiology of disease Volume 193, April 2024, 106437].
Godoy-Corchuelo JM, Ali Z, Brito Armas JM, Martins-Bach AB, García-Toledo I, Fernandez-Beltrán LC, Lopez-Carbonero JI, Bascunana P, Spring S, Jimenez-Coca I, Muñozde Bustillo Alfaro RA, Sanchez-Barrena MJ, Nair RR, Nieman BJ, Lerch JP, Miller KL, Ozdinler HP, Fisher EMC, Cunningham TJ, Acevedo-Arozena A, Corrochano S. Godoy-Corchuelo JM, et al. Among authors: miller kl. Neurobiol Dis. 2024 Nov;202:106708. doi: 10.1016/j.nbd.2024.106708. Epub 2024 Oct 28. Neurobiol Dis. 2024. PMID: 39462744 Free PMC article. No abstract available.
Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction.
Wood GK, Sargent BF, Ahmad ZU, Tharmaratnam K, Dunai C, Egbe FN, Martin NH, Facer B, Pendered SL, Rogers HC, Hübel C, van Wamelen DJ, Bethlehem RAI, Giunchiglia V, Hellyer PJ, Trender W, Kalsi G, Needham E, Easton A, Jackson TA, Cunningham C, Upthegrove R, Pollak TA, Hotopf M, Solomon T, Pett SL, Shaw PJ, Wood N, Harrison NA, Miller KL, Jezzard P, Williams G, Duff EP, Williams S, Zelaya F, Smith SM, Keller S, Broome M, Kingston N, Husain M, Vincent A, Bradley J, Chinnery P, Menon DK, Aggleton JP, Nicholson TR, Taylor JP, David AS, Carson A, Bullmore E, Breen G, Hampshire A; COVID-CNS Consortium; Michael BD, Paddick SM, Leek EC. Wood GK, et al. Among authors: miller kl. Nat Med. 2025 Jan;31(1):245-257. doi: 10.1038/s41591-024-03309-8. Epub 2024 Sep 23. Nat Med. 2025. PMID: 39312956
470 results